


RGX-104

Cat. No.:	HY-111498A
CAS No.:	610318-54-2
Molecular Formula:	C ₃₄ H ₃₃ ClF ₃ NO ₃
Molecular Weight:	596.08
Target:	LXR
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (167.76 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.6776 mL	8.3881 mL	16.7763 mL
		5 mM		0.3355 mL	1.6776 mL	3.3553 mL
		10 mM		0.1678 mL	0.8388 mL	1.6776 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.17 mg/mL (3.64 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (3.49 mM); Suspended solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.83 mg/mL (1.39 mM); Clear solution 					

BIOLOGICAL ACTIVITY

Description	RGX-104 is an orally bioavailable and potent liver-X nuclear hormone receptor (LXR) agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
IC₅₀ & Target	LXR ^[1]
In Vivo	Oral administration of RGX-104 (100 mg/kg, daily) to animals bearing palpable tumors significantly suppresses the growth of multiple cancer types. Co-administration of RGX-104 with anti-PD-1 is superior to administration of either RGX-104 or anti-PD-1 alone. Importantly, co-administration of RGX-104 with anti-PD-1 therapy is well tolerated by mice, with no overt signs of toxicity ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD SCID or RAG mice injected with 1×10^6 SKOV3 ovarian cancer cells ^[1] .
Dosage:	100 mg/kg.
Administration:	Oral administration daily for about 60 days.
Result:	Robustly suppressed tumor growth and progression.

REFERENCES

[1]. Tavazoie MF, et al. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018 Feb 8;172(4):825-840.e18.

Caution: Product has not been fully validated for medical applications. For research use only.

India Contact:

Life Technologies (India) Pvt. Ltd.

306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444

Email: customerservice@lifetechindia.com Website: www.lifetechindia.com